Jinbo Biotech (920982) has released a formal statement addressing the irregularities in the aesthetic medicine industry exposed by the 3·15 Gala, clarifying misconceptions, outlining compliance standards, and issuing risk warnings to consumers and practitioners.
According to the 3·15 Gala report, products such as "Qing Cheng" from XXX Biotech Co., Ltd. were found to be using a Class II medical device license for humanized collagen to illegally market products containing exosome components. Jinbo Biotech stated that such "license borrowing" practices not only violate the "Regulations on the Supervision and Administration of Medical Devices" but also involve injecting substances into the human body without safety verification, disregarding consumer health. Furthermore, these actions disrupt market order and damage the reputation of compliant humanized collagen enterprises.
Jinbo Biotech expressed firm support for the National Medical Products Administration's efforts to crack down on such illegal activities, uphold safety standards in the aesthetic medicine market, and maintain a zero-tolerance policy towards improper license usage.
In its statement, Jinbo Biotech clarified regulatory requirements, emphasizing that injectable products intended for human dermal tissue or circulation are classified as high-risk Class III medical devices. These must undergo rigorous pharmaceutical studies, clinical trials, and regulatory review, obtaining a "Medical Device Approval No. 3" registration certificate before market release. Class II medical devices are only approved for non-invasive or superficial use and are strictly prohibited for injection purposes. The company also highlighted that no exosome-based drugs have been approved for market release in China, nor have any medical devices containing "exosomes" as an ingredient been authorized. All injectable exosome products currently on the market are non-compliant, with unverified safety and efficacy, and consumers are advised to exercise caution.
Jinbo Biotech disclosed its own compliance credentials, noting it is the only company in China holding three Class III medical device registration certificates for products primarily categorized as "humanized collagen," approved by the National Medical Products Administration. The registration numbers are National Medical Device Approval 20213130488, 20233131245, and 20253130751. The company attributed these certifications to its long-term commitment to scientific research, strict clinical validation, and standardized production, underscoring their role as core evidence of product compliance and safety.
The company advised consumers and practitioners to recognize legal boundaries, insisting that injectable products must carry Class III medical device registration certificates. It also urged vigilance against "license borrowing" schemes, recommending careful verification of product names, ingredients, and intended uses to avoid deception by unscrupulous sellers. Before any procedure, individuals can check the National Medical Products Administration website to confirm product registration details and ensure legality.
Jinbo Biotech's core business involves the research, development, production, and sale of medical devices and functional skincare products centered on recombinant collagen and anti-HPV biological proteins. On June 29, 2021, the company's self-developed Class III medical device, "Recombinant Type III Humanized Collagen Freeze-Dried Fiber," received market approval from the National Medical Products Administration. This product represents China's first medical device developed using the novel biomaterial recombinant humanized collagen, laying a solid foundation for clinical application and industrial transformation.
On July 20, 2023, Jinbo Biotech was listed on the Beijing Stock Exchange, becoming the first recombinant collagen-focused stock on the exchange. As of March 16, the company's market capitalization reached 20.942 billion yuan, ranking third on the Beijing Stock Exchange.